Phenoxyether derivatives as PPAR modulators
AssigneeEli Lilly and Company
InventorsLeonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
Claims18
The compound having a structural formula III,
- or a pharmaceutically acceptable salt thereof wherein:
- A is:
- a bond, CH2, (CH2)2, O, S;
- or A and R1 or A and R2 together being a 3- to 6-membered carbocyclyl when A is a carbon;
- n is:
- 1, 2, 3, 4, 5 or 6
- p is:
- 1 or 2;
- r is:
- 1, 2, 3, or 4;
- R1 and R2 are each independently:
- hydrogen, C1-C6 alkyl, or R1 and R2 together being a 3- to 8-membered carbocyclic ring;
- R3 and R4 are each independently:
- hydrogen,
- nitro,
- cyano,
- hydroxyl,
- halo,
- haloalkyl,
- haloalkyloxy,
- C1-C6 alkyl,
- C1-C6 alkoxy, or
- C3-C8 cycloalkyl
- R5 is:
- hydrogen,
- nitro,
- cyano,
- hydroxyl,
- halo,
- haloalkyl,
- haloalkyloxy,
- aryloxy,
- C1-C6 alkyl,
- C1-C6 alkoxy,
- [T]-aryl,
- [T]-heteroaryl,
- [T]-heterocyclyl,
- [T]-(CH2)n, C3-C8 cycloalkyl,
- C(O)pR7,
- O(CH2)nR7,
- SR7,
- S(O)pR7 or
- OS(O)pR7,
- wherein aryl, aryloxy, alkyl, heteroaryl, heterocyclyl and cycloalkyl are being optionally substituted with one or more substituents independently selected from R8;
- [T] is:
- a bond, O, C(O), S, NR7, or C1-C6 alkyl;
- R6 is:
- hydrogen, C1-C6 alkyl or aminoalkyl;
- R7 is:
- hydrogen,
- C1-C6 alkyl,
- C3-C8 cycloalkyl,
- aryl,
- heteroaryl or
- heterocyclyl,
- wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents independently selected from R8;
- and
- R8 is:
- hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, acyl, C1-C6 alkyl, C1-C6 alkoxy or C3-C8 cycloalkyl.
The compound having the structural formula X,
- or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
- is a 5- or 6-membered heteroaryl or heterocyclyl, wherein heteroaryl and heterocyclyl being optionally substituted with one or more substituents independently selected from R8;
- A is:
- a bond, CH2, (CH2)2, O, S;
- or A and R1 or A and R2 together being a 3- to 6-membered carbocyclyl when A is a carbon;
- n is:
- 1,2,3,4,5 or 6;
- p is:
- 1 or 2;
- r is:
- 1,2,3, or 4;
- R1 and R2 are each independently:
- hydrogen, C1-C6 alkyl, or R1 and R2 together being a 3- to 8-membered carbocyclic ring;
- R3 and R4 are each independently:
- hydrogen,
- nitro,
- cyano,
- hydroxyl,
- halo,
- haloalkyl,
- haloalkyloxy,
- C1-C6 alkyl,
- C1-C6 alkoxy, or
- C3-C8 cycloalkyl
- R5 is:
- hydrogen,
- nitro,
- cyano,
- hydroxyl,
- halo,
- haloalkyl,
- haloalkyloxy,
- aryloxy,
- C1-C6 alkyl,
- C1-C6 alkoxy,
- [T]-aryl,
- [T]-heteroaryl,
- [T]-heterocyclyl,
- [T]-(CH2)nC3-C8 cycloalkyl,
- C(O)pR7,
- O(CH2)nR7,
- SR7,
- S(O)pR7 or
- OS(O)pR7,
- wherein aryl, aryloxy, alkyl, heteroaryl, heterocyclyl and cycloalkyl are being optionally substituted with one or more substituents independently selected from R8;
- [T] is:
- a bond, O, C(O), S, NR7, or C1-C6 alkyl;
- R6 is:
- hydrogen, C1-C6 alkyl or aminoalkyl;
- R7 is:
- hydrogen,
- C1-C6 alkyl,
- C3-8 cycloalkyl,
- aryl,
- heteroaryl or
- heterocyclyl,
- wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents independently selected from R8, and
- R8 is:
- hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, acyl, C1-C6 alkyl, C1-C6 alkoxy or C3-C8 cycloalkyl.
The compound having the structural formula XII,
- or a pharmaceutically acceptable salt or stereoisomer thereof;
- A is:
- a bond, CH2, (CH2)2, O, S;
- or A and R1 or A and R2 together being a 3- to 6-membered carbocyclyl when A is a carbon;
- Q is COOR6;
- n is:
- 1,2,3,4,5 or 6;
- p is:
- 1 or 2;
- r is:
- 1,2,3, or 4;
- R1 and R2 are each independently:
- hydrogen, C1-C6 alkyl, or R1 and R2 together being a 3- to 8-membered carbocyclic ring;
- R3 and R4 are each independently:
- hydrogen,
- nitro,
- cyano,
- hydroxyl,
- halo,
- haloalkyl,
- haloalkyloxy,
- C1-C6 alkyl,
- C1-C6 alkoxy, or
- C3-C8 cycloalkyl
- R5 is:
- hydrogen,
- nitro,
- cyano,
- hydroxyl,
- halo,
- haloalkyl, haloalkyloxy,
- aryloxy,
- C1-C6 alkyl,
- C1-C6 alkoxy,
- [T]-aryl,
- [T]-heteroaryl,
- [T]-heterocyclyl,
- [T]-(CH2)nC3-C8 cycloalkyl,
- C(O)pR7,
- O(CH2)nR7,
- SR7,
- S(O)pR7, or
- OS(O)pR7,
- wherein aryl, aryloxy, alkyl, heteroaryl, heterocyclyl and cycloalkyl are being optionally substituted with one or more substituents independently selected from R8;
- [T] is:
- a bond, O, C(O), S, NR7, or C1-C6 alkyl;
- R6 is:
- hydrogen, C1-C6 alkyl or aminoalkyl;
- R7 is:
- hydrogen,
- C1-C6 alkyl,
- C3-C8 cycloalkyl,
- aryl,
- heteroaryl or
- heterocyclyl,
- wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents independently selected from R8;
- and
- R8 is:
- hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, acyl, C1-C6 alkyl, C1-C6 alkoxy or C3-C8 cycloalkyl.
A compound selected from the group consisting of the following compounds:
- No.
- Structure
- Name
- 1
- 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 2
- 3-{4-[3-(2-Benzoyl-4- ethyl-phenoxy)-phenoxy]- 2-methyl-phenyl}- propionic acid
- 3
- 3-{4-[3-(4-Ethyl-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 4
- 3-{4-[3-(2-Benzoyl-4- chloro-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 5
- 3-{4-[3-(2-Benzoyl- phenoxy)-phenoxy]-2- methyl-phenyl}-propionic acid
- 6
- 3-{2-Methyl-4-[3-(2- phenoxy-phenoxy)- phenoxy]-phenyl}- propionic acid
- 7
- 3-{2-Methyl-4-[3-(2- phenoxy-4- trifluoromethyl-phenoxy)- phenoxy]-phenyl}- propionic acid
- 8
- 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)-5- fluoro-phenoxy]-2-methyl- phenyl}-propionic acid
- 9
- 3-{4-[3-(4-Ethyl-2- phenoxy-phenoxy)-5- fluoro-phenoxy]-2-methyl- phenyl}-propionic acid
- 10
- 3-(4-{3-[4-Ethyl-2-(1- methyl-1-phenyl-ethyl)- phenoxy]-5-fluoro- phenoxy}-2-methyl- phenyl)-propionic acid
- 11
- 3-{4-[3-(4-Ethyl-2- phenoxy-phenoxy)-5- fluoro-phenoxy]-2-methyl- phenyl}-propionic acid
- 12
- 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)-5- methyl-phenoxy]-2- methyl-phenyl}-propionic acid
- 13
- 3-{4-[3-(2-Benzoyl-4- chloro-phenoxy)-5- methyl-phenoxy]-2- methyl-phenyl}-propionic acid
- 14
- 3-{2-Methyl-4-[3-methyl- 5-(2-pyridin-3-yl-4- trifluoromethyl-phenoxy)- phenoxy]-phenyl}- propionic acid
- 15
- 3-{2-Methyl-4-[3-methyl- 5-(2-pyridin-2-yl-4- trifluoromethyl-phenoxy)- phenoxy]-phenyl}- propionic acid
- 16
- 3-{4-[3-(2′-Acetyl-5- trifluoromethyl-biphenyl- 2-yloxy)-5-methyl- phenoxy]-2-methyl- phenyl}-propionic acid
- 17
- 3-{4-[3-(4′- Methanesulfonyl-5- trifluoromethyl-biphenyl- 2-yloxy)-5-methyl- phenoxy]-2-methyl- phenyl}-propionic acid
- 18
- 3-{2-Methyl-4-[3-methyl- 5-(2′-trifluoromethoxy-5- trifluoromethyl-biphenyl- 2-yloxy)-phenoxy]- phenyl}-propionic acid
- 19
- 3-{2-Methyl-4-[3-methyl- 5-(2-phenoxy-4- trifluoromethyl-phenoxy)- phenoxy]-phenyl}- propionic acid
- 20
- 3-(2-Methyl-4-{3-methyl- 5-[2-(pyridin-2-yloxy)-4- trifluoromethyl-phenoxy]- phenoxy}-phenyl)- propionic acid
- 21
- 3-(2-Methyl-4-{3-methyl- 5-[2-(2-oxo-2H-pyridin-1- yl)-4-trifluoromethyl- phenoxy]-phenoxy}- phenyl)-propionic acid
- 22
- 3-(2-Methyl-4-{3-methyl- 5-[2-(pyridin-3-yloxy)-4- trifluoromethyl-phenoxy]- phenoxy}-phenyl)- propionic acid
- 23
- 3-{2-Methyl-4-[3-methyl- 5-(2-o-tolyloxy-4- trifluoromethyl-phenoxy)- phenoxy]-phenyl}- propionic acid
- 24
- 3-{2-Methyl-4-[3-methyl- 5-(2-m-tolyloxy-4- trifluoromethyl-phenoxy)- phenoxy]-phenyl}- propionic acid
- 25
- 3-{2-Methyl-4-[3-methyl- 5-(2-p-tolyloxy-4- trifluoromethyl-phenoxy)- phenoxy]-phenyl}- propionic acid
- 26
- 3-(4-{3-[2-(3,5-Difluoro- phenoxy)-4- trifluoromethyl-phenoxy]- 5-methyl-phenoxy}-2- methyl-phenyl)-propionic acid
- 27
- 3-{4-[3-Fluoro-5-(2- phenoxy-4- trifluoromethyl-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 28
- 3-{4-[3-Fluoro-5-(2- pyridin-2-yl-4- trifluoromethyl-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 29
- 3-{4-[3-Fluoro-5-(2- pyridin-3-yl-4- trifluoromethyl-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 30
- 3-{4-[3-Chloro-5-(2- phenoxy-4- trifluoromethyl-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 31
- 3-(4-{3-Chloro-5-[2-(3- fluoro-phenoxy)-4- trifluoromethyl-phenoxy]- phenoxy}-2-methyl- phenyl)-propionic acid
- 32
- 3-{4-[3-Chloro-5-(2- pyridin-2-yl-4- trifluoromethyl-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 33
- 3-{4-[3-Chloro-5-(2- pyridin-3-yl-4- trifluoromethyl-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 34
- {4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenylsulfanyl}-acetic acid
- 35
- 2-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-phenoxy}-2- methyl-propionic acid
- 36
- 2-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenoxy}-2-methyl- propionic acid
- 37
- {4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenoxy}-acetic acid
- 38
- 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-fluoro- phenyl}-propionic acid
- 39
- 4-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-butyric acid
- 40
- 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-ethyl-phenyl}- propionic acid
- 41
- 3-{4-[3-(2-Benzyl-4- chloro-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid
- 42
- 3-{4-[3-(2-Benzyl-4- chloro-phenoxy)-5- methyl-phenoxy]-2- methyl-phenyl}-propionic acid
- 43
- 3-{4-[3-(4-Chloro-2- cyclohexyl-phenoxy)-5- methyl-phenoxy]-2- methyl-phenyl}-propionic acid
- 44
- 3-{4-[3-(2-Benzyl-4- chloro-phenoxy)-5-fluoro- phenoxy]-2-methyl- phenyl}-propionic acid
- 45
- 3-{2-Methyl-4-[3-methyl- 5-(3-phenoxy-5- trifluoromethyl-pyridin-2- yloxy)-phenoxy]-phenyl}- propionic acid.
Dependencies are inferred from the claim text.